September 22, 2022 – Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults “The Pfizer trial exhibited a 36 % higher risk of serious adverse events in vaccinated participants in comparison to placebo recipients: 67.5 per 10,000 versus 49.5 per 10,000; risk difference 18.0 per 10,000 vaccinated participants (95 % compatibility1 interval 1.2 to 34.9); risk ratio 1.36 (95 % CI 1.02 to 1.83). The Moderna trial exhibited a 6 % higher risk of SAEs in vaccinated individuals compared to those receiving placebo
September 22, 2022 – No significant increase in Guillain-Barré syndrome after COVID-19 vaccination in adults: A vaccine adverse event reporting system study In our study, several lines of evidence suggest that in some cases, the association between GBS and COVID-19 vaccination is not entirely coincidental. Firstly, the increased reporting rate of GBS within the first 6 weeks after vaccination. 64 % of cases were reported after 6 weeks of COVID-19 vaccination. Self-controlled and case centered analyses confirmed a greater relative risk of GBS within the risk period compared to control period. Similar results were observed in several studies that suspected or established an association between some cases of GBS and vaccination.